{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:35:00Z","timestamp":1762428900652,"version":"build-2065373602"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Adenoid Cystic Carcinoma (ACC) is characterized by its aggressive nature, high propensity for perineural invasion, and significant risk of distant metastasis, particularly to the lungs. Therapeutic options for locally advanced or metastatic ACC are limited, and conventional radiotherapy is often constrained by dose limitations for multifocal disease, leading to inadequate treatment. A 54-year-old male ACC patient, who had recurred after three prior surgeries, presented with PET\/CT-confirmed bilateral cervical lymph node and multiple bilateral pulmonary metastases. Given the multifocal metastases and the critical need for sparing organs at risk (lungs, heart, esophagus), which rendered photon radiotherapy unable to meet the required dose constraints, proton therapy was employed with the following dose prescriptions: for pulmonary metastases: CTV 50 Gy(RBE) in 15 fractions, GTV 60 Gy(RBE) in 15 fractions; for the cervical lesion: GTVnd 70 Gy(RBE) in 28 fractions, CTVnd 66 Gy(RBE) in 28 fractions, CTV 50.4 Gy(RBE) in 28 fractions. Follow-up PET\/CT post-treatment demonstrated complete resolution of some bilateral pulmonary metastases, with marked reduction in size and decreased metabolism in the remaining nodules. The metastatic cervical lymph nodes also showed reduced volume and metabolic activity. No adverse events exceeding Grade 2 occurred during the treatment course. This case demonstrates that proton therapy is highly suitable for multifocal ACC metastases, especially multiple small pulmonary nodules. Through its precise dose delivery, it enables high-dose irradiation (GTV 60\u201370 Gy(RBE)) to targets while significantly sparing normal organs. This approach represents a viable strategy for complex cases where conventional radiotherapy is contraindicated. It aims to delay disease progression and achieve organ preservation in refractory ACC.<\/jats:p>","DOI":"10.3389\/fonc.2025.1669420","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:29:00Z","timestamp":1762406940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton therapy achieves high-dose tumor control with organ preservation in complex metastatic adenoid cystic carcinoma: a case report of a refractory patient with 16 pulmonary metastases"],"prefix":"10.3389","volume":"15","author":[{"given":"Zejun","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqiang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zishen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingrong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.ctro.2025.100945","article-title":"Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis","volume":"53","author":"Dou","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35901","article-title":"Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma","volume":"131","author":"Hoff","year":"2025","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02795-4","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review of the last decade","volume":"131","author":"Zhou","year":"2024","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1748-717X-8-71","article-title":"Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery","volume":"8","author":"MacDonald","year":"2013","journal-title":"Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32776","article-title":"Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus Malignancies","volume":"126","author":"Fan","year":"2020","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103410","DOI":"10.1016\/j.ejmp.2024.103410","article-title":"Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era","volume":"123","author":"Dionisi","year":"2024","journal-title":"Phys Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110935","DOI":"10.1016\/j.radonc.2025.110935","article-title":"A systematic review and meta-analysis of the utility of quantitative, imaging-based approaches to predict radiation-induced toxicity in lung cancer patients","volume":"208","author":"Tong","year":"2025","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.01.036","article-title":"International particle therapy co-operative group (PTCOG) thoracic subcommittee. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer","volume":"95","author":"Chang","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/ol.2025.14899","article-title":"Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review)","volume":"29","author":"Stawarz","year":"2025","journal-title":"Oncol Lett"},{"key":"B10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3109\/0284186X.2013.831186","article-title":"The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia","volume":"53","author":"Beetz","year":"2014","journal-title":"Acta Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"103722","DOI":"10.1016\/j.esmoop.2024.103722","article-title":"Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review","volume":"9","author":"Prost","year":"2024","journal-title":"ESMO Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100749","DOI":"10.1016\/j.ijpt.2025.100749","article-title":"First clinical implementation of step-and-shoot proton arc therapy for head and neck cancer treatment","volume":"16","author":"Liu","year":"2025","journal-title":"Int J Part Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.846278","article-title":"Neurotropic cutaneous Malignancies: case report on keratinocyte derived Malignancies of the head and neck with perineural invasion","volume":"12","author":"Ahn","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1236_21","article-title":"Proton therapy for skull-base adenoid cystic carcinomas: A case series and review of literature","volume":"18","author":"Nangia","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.11.031","article-title":"Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck","volume":"113","author":"Takagi","year":"2014","journal-title":"Radiother Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50343","article-title":"Proton beam therapy for lung oligometastatic recurrence in patients with esophageal cancer","volume":"15","author":"Yamaguchi","year":"2023","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.ijpt.2024.100013","article-title":"Dosimetric evaluation of target motion effects in spot-scanning proton therapy: A phantom study","volume":"11","author":"Belikhin","year":"2024","journal-title":"Int J Part Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2023.24.11.3643","article-title":"A systematic review of the economic burden of proton therapy in head and neck cancer","volume":"24","author":"Bharathi","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.07.007","article-title":"Charged particle beams to cure cancer: Strengths and challenges","volume":"46","author":"Durante","year":"2019","journal-title":"Semin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41571-022-00697-z","article-title":"Towards clinical translation of FLASH radiotherapy","volume":"19","author":"Vozenin","year":"2022","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:30:05Z","timestamp":1762428605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1669420"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669420","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1669420"}}